Skip to main content
Research examines safety of proinsulin peptide immunotherapy in diabetes

Patients with new-onset type 1 diabetes did not experience accelerated declines of beta cell function if they received intradermal injections of human leukocyte antigen-DR4-restricted immunodominant proinsulin peptide, according to a study in Science Translational Medicine. The placebo group used 50% more daily insulin after a year, while insulin use remained steady in the treatment group.

Full Story: